KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Equity (2016 - 2025)

Historic Return on Equity for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to 0.32%.

  • CRISPR Therapeutics AG's Return on Equity fell 1100.0% to 0.32% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.32%, marking a year-over-year decrease of 1100.0%. This contributed to the annual value of 0.32% for FY2025, which is 1000.0% down from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Return on Equity stood at 0.32%, which was down 1100.0% from 0.29% recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year Return on Equity high stood at 0.2% for Q2 2021, and its period low was 0.34% during Q4 2022.
  • Moreover, its 5-year median value for Return on Equity was 0.22% (2024), whereas its average is 0.16%.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Return on Equity soared by 3900bps in 2021, and later crashed by -4900bps in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Return on Equity (Quarter) stood at 0.15% in 2021, then tumbled by -322bps to 0.34% in 2022, then skyrocketed by 70bps to 0.1% in 2023, then crashed by -106bps to 0.21% in 2024, then plummeted by -52bps to 0.32% in 2025.
  • Its last three reported values are 0.32% in Q4 2025, 0.29% for Q3 2025, and 0.29% during Q2 2025.